Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.68 -0.01 (-0.01%) 5:26 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.68 -0.01 (-0.01%) 5:26 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Zacks News
Growth in New Drugs to Give a Boost to Roche (RHHBY) Q1 Sales
by Zacks Equity Research
Roche's (RHHBY) newer drugs are likely to have combated the biosimilar competition for legacy drugs in the first quarter.
Incyte Gets FDA Nod for Cholangiocarcinoma Drug Pemazyre
by Zacks Equity Research
Incyte (INCY) gets FDA approval for Pemazyre for the treatment of previously-treated, unresectable, locally-advanced or metastatic cholangiocarcinoma.
Regeneron's BLA for Ebola Vaccine Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts Regeneron's (REGN) BLA for REGN-EB3 under a priority review to treat the deadly Ebola virus infection. A verdict is pending on Oct 25, 2020.
Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts
by Kinjel Shah
J&J (JNJ) announces Q1 results. Several companies offer update on their studies/plans to make coronavirus treatments or vaccines
Merck (MRK) Stock Moves -0.93%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $82.07, moving -0.93% from the previous trading session.
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
J&J (JNJ) Beats on Q1 Earnings, Cuts View on Coronavirus Impact
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2020. It lowers its adjusted earnings and sales outlook for 2020 for coronavirus-related uncertainty. Stock up.
AstraZeneca's Koselugo Gets FDA Nod for Rare Genetic Disorder
by Zacks Equity Research
The FDA approves AstraZeneca (AZN) and Merck's kinase inhibitor, Koselugo, for treating pediatric patients with neurofibromatosis type 1 (NF1) having symptomatic, inoperable plexiform neurofibromas.
Will J&J's Pharma Unit Perform Above Market to Drive Q1 Result?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is delivering an above-market performance despite currency headwinds and the impact of biosimilar and generic competition.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $82.46, moving +1.03% from the previous trading session.
J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on J&J's (JNJ) performance when it reports first-quarter results.
Bristol Myers' Applications for Opdivo-Yervoy Combo Accepted
by Zacks Equity Research
Bristol Myers' (BMY) applications for Opdivo in combination with Yervoy administered concomitantly with a limited course of chemotherapy have been accepted in the United States and Europe.
Merck's Keytruda Gets FDA's Priority Review for Solid Tumors
by Zacks Equity Research
Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's priority review.
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC
by Zacks Equity Research
The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).
Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.
Esperion's Cholesterol Drugs Receive Approval in Europe
by Zacks Equity Research
Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.
Immunomedics Up as Breast Cancer Drug Study Shows Efficacy
by Zacks Equity Research
Immunomedics (IMMU) soars as the phase III study on breast cancer drug shows efficacy and will be subsequently halted.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck & Co, Novartis, PayPal and IBM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck & Co, Novartis, PayPal and IBM
3 Stocks Immune to the Coronavirus Downturn to Buy Right Now
by Benjamin Rains
Today's episode of Full Court Finance here at Zacks quickly dives into why Wall Street seems optimistic on Monday. Despite the positivity, investors should still be on the hunt for stocks that appear immune to the broader coronavirus fallout...
The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck
Top Stock Reports for J&J, Merck, Novartis & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Merck (MRK) and Novartis (NVS).
Merck (MRK) Stock Moves -0.81%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $76.25 in the latest trading session, marking a -0.81% move from the prior day.
Why Merck (MRK) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Seattle Genetics Issue Update on Padcev Label Expansion Study
by Zacks Equity Research
Seattle Genetics (SGEN) may receive an expedited approval pathway for Padcev combo to treat patients with locally advanced/metastatic urothelial cancer in the first-line setting in the United States.
Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates
by Kinjel Shah
J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.